Lasting controversy on ranibizumab and bevacizumab.
Lasting controversy on ranibizumab and bevacizumab.
复制标题
雷珠单抗和贝伐单抗的持久争议
DOI：
10.7150/thno/v01p0395
复制
发表时间：
2011
期刊：
影响因子：
12.4
通讯作者：
Xiao F
中科院分区：
文献类型：
--
作者：
Zou L;Lai H;Zhou Q;Xiao F
Vascular endothelial growth factor (VEGF), an important angiogenic factor that is able to stimulate the proliferation and migration of endothelial cells, is the best-studied hallmark of angiogenesis. Neovascularization is a major cause of age-related macular degeneration (AMD) which is a leading cause of blindness in the elderly population. Specific molecular inhibitors of VEGF have been proved to be useful in the treatment of AMD. Ranibizumab and Bevacizumab are structurally similar to anti-VEGF drugs in the treatment of AMD. Many studies have indicated that Ranibizumab and Bevacizumab are of roughly equal short-term efficacy and safety, Bevacizumab is an attractive alternative to Ranibizumab due to its lower cost. However, only Ranibizumab has received Food and Drug Administration (FDA) approval for the treatment of macular degeneration. More multicenter clinical trials are required to compare the relative efficacy and safety of these two drugs and some progress has been achieved. This review discusses the clinical effectiveness, safety, cost and other practical implications of Ranibizumab and Bevacizumab.
登录
查看更多内容
影响因子：
4.2
作者：
Ferrara, Daniela C.;Koizumi, Hideki;Spaide, Richard F.
通讯作者：
Spaide, Richard F.
影响因子：
4.4
作者：
Gaudreault, J;Fei, D;Shiu, V
通讯作者：
Shiu, V
影响因子：
158.5
作者：
Brown, David M.;Kaiser, Peter K.;Schneider, Susan
通讯作者：
Schneider, Susan
DOI：
10.1097/iae.0b013e318217ffde
发表时间：
2011-06-01
影响因子：
3.3
作者：
Choi, Daniel Y.;Ortube, Maria Carolina;Gorin, Michael B.
通讯作者：
Gorin, Michael B.
DOI：
10.1073/pnas.041359198
发表时间：
2001-02-27
影响因子：
11.1
作者：
Fukumura, D;Gohongi, T;Jain, RK
通讯作者：
Jain, RK